vaccinatie tegen pneumokokken (bacterële infectie), en tegen griep (virale infecties), immuunsysteem COVID-19 vaccination response
Conditions
Interventions
None listed
Sponsors
RIVM
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -Born between 1941-1947 (73-79 years of age) -COVID-19 group: Having had a proven (SARS-CoV-2 PCR test positive) COVID-19 infection at least 1 month before study entry -Control group: Have not had a positive SARS-CoV-2 PCR test -Willing to receive the PPV23 vaccine -Be capacitated -Have signed Informed Consent
Exclusion criteria
Exclusion criteria: -Having had a previous pneumococcal vaccination (PCV or the 23-valent pneumococcal polysaccharide vaccine (PPV23)).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pneumococcal serotype- specific serum IgG antibody concentrations (GMCs) pre-vaccination and four weeks post PPV23 vaccination measured by bead-based multiplex immune assay. | — |
Secondary
| Measure | Time frame |
|---|---|
| Influenza vaccine strain-specific serum IgG antibody titers (GMTs) will be measured pre- vaccination and four weeks post-influenza vaccination by Hemagglutinin Inhibition (HI) assay Pneumococcal serotype-specific IgM and IgA antibody titers in serum pre- and post-vaccination Health status assessment will be done by questionnaires. Exploratory: Cross-reactive antibodies against other previous coronaviruses infections COVID-19 details, including, onset, symptoms and severity | — |
Countries
Netherlands
Outcome results
None listed